Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
暂无分享,去创建一个
Clara D. Christ | O. Fedorov | S. Müller | B. Haendler | C. Tallant | K. Huber | J. Bennett | Detlef Stöckigt | L. Diaz-saez | A. ter Laak | Ingo V. Hartung | V. Pütter | Octovia P. Monteiro | J. Weiske | A. Fernández-Montalván | S. Siegel | Léa Bouché | S. Holton | T. Sugawara | P. Siejka | J. Meier | Amaury E. Fernández-Montalván | I. Hartung
[1] S. Knapp,et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. , 2017, Journal of medicinal chemistry.
[2] Karen E Gascoigne,et al. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. , 2016, Journal of medicinal chemistry.
[3] S. Knapp,et al. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.
[4] C. Arrowsmith,et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. , 2016, Journal of medicinal chemistry.
[5] Vassilios Myrianthopoulos,et al. Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis , 2016, Journal of medicinal chemistry.
[6] R. Prinjha,et al. Clinical progress and pharmacology of small molecule bromodomain inhibitors. , 2016, Current opinion in chemical biology.
[7] Min Seong Kim,et al. The BRPF2/BRD1-MOZ complex is involved in retinoic acid-induced differentiation of embryonic stem cells. , 2016, Experimental cell research.
[8] Christoph Bock,et al. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. , 2016, Nature chemical biology.
[9] Andrew C Good,et al. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. , 2016, Journal of medicinal chemistry.
[10] David J. Fallon,et al. GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain , 2016, ACS medicinal chemistry letters.
[11] C. Petosa,et al. Bromodomains: Structure, function and pharmacology of inhibition. , 2016, Biochemical pharmacology.
[12] Clara D. Christ,et al. Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2 , 2016, Journal of medicinal chemistry.
[13] E. Nogales,et al. Structure of promoter-bound TFIID and insight into human PIC assembly , 2016, Nature.
[14] Kyle V. Butler,et al. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. , 2016, ACS chemical biology.
[15] F. A. Romero,et al. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.
[16] Andrew J. Bannister,et al. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.
[17] S. Knapp,et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor , 2016, Journal of medicinal chemistry.
[18] G. Poncet-Montange,et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. , 2016, Journal of medicinal chemistry.
[19] R. Shamir,et al. Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism , 2016, Cellular and Molecular Life Sciences.
[20] B. Haendler,et al. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs , 2016, Expert opinion on therapeutic targets.
[21] Jennifer L. Knight,et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.
[22] Xiang-Jiao Yang,et al. The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival* , 2015, The Journal of Biological Chemistry.
[23] Edward Yang,et al. TAF1 Variants Are Associated with Dysmorphic Features, Intellectual Disability, and Neurological Manifestations , 2015, American journal of human genetics.
[24] Susanne Müller,et al. Open access chemical probes for epigenetic targets , 2015, Future medicinal chemistry.
[25] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[26] Marie Jung,et al. Targeting BET bromodomains for cancer treatment. , 2015, Epigenomics.
[27] K. Wood,et al. NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.
[28] S. Knapp,et al. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF , 2015, Journal of medicinal chemistry.
[29] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[30] E. Wang,et al. The Chromatin Regulator Brpf1 Regulates Embryo Development and Cell Proliferation* , 2015, The Journal of Biological Chemistry.
[31] Andreas H. Göller,et al. Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology To Improve in Silico pKa Prediction , 2015, J. Chem. Inf. Model..
[32] Wei Zhang,et al. Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors , 2014, Journal of medicinal chemistry.
[33] David J. Fallon,et al. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. , 2014, ACS medicinal chemistry letters.
[34] Junwei Shi,et al. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.
[35] Nicola J. Richmond,et al. Validity of ligand efficiency metrics. , 2014, ACS medicinal chemistry letters.
[36] S. Knapp,et al. Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.
[37] S. Müller,et al. Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1 , 2014, The Journal of Biological Chemistry.
[38] K. Gupta,et al. More pieces to the puzzle: recent structural insights into class II transcription initiation. , 2014, Current opinion in structural biology.
[39] Xiang-Jiao Yang,et al. Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes , 2014, Epigenetics.
[40] P. Sandy,et al. Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. , 2013, ACS medicinal chemistry letters.
[41] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[42] S. Knapp,et al. Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.
[43] S. Dusuel,et al. Topological phase transitions in the golden string-net model. , 2012, Physical review letters.
[44] S. Knapp,et al. Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.
[45] Nathan Brown,et al. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.
[46] David M. Wilson,et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.
[47] S. Hatakeyama,et al. TRIM proteins and cancer , 2011, Nature Reviews Cancer.
[48] S. Knapp,et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.
[49] O. Hucke,et al. Assessing atropisomer axial chirality in drug discovery and development. , 2011, Journal of medicinal chemistry.
[50] A. Iwama,et al. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. , 2011, Blood.
[51] Stefan Knapp,et al. Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.
[52] S. Knapp,et al. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.
[53] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[54] O. Hucke,et al. Revealing Atropisomer Axial Chirality in Drug Discovery , 2011, ChemMedChem.
[55] G. Bringmann,et al. Atroposelective total synthesis of axially chiral biaryl natural products. , 2011, Chemical reviews.
[56] Vincent B. Chen,et al. MolProbity: all-atom structure validation for macromolecular crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.
[57] S. LaPlante,et al. The challenge of atropisomerism in drug discovery. , 2009, Angewandte Chemie.
[58] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[59] M. Ōki. Recent Advances in Atropisomerism , 2007 .
[60] D. Page,et al. Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis. , 2002, Human molecular genetics.
[61] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[62] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[63] M. A. Patrick,et al. A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography. , 1988, Journal of medicinal chemistry.
[64] H. Shimada,et al. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ–TIF2 fusion , 2013, International Journal of Hematology.
[65] Stefan Knapp,et al. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.
[66] Clemens Vonrhein,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[67] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[68] Serge X. Cohen,et al. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 , 2008, Nature Protocols.
[69] Ballard,et al. Overview of the CCP 4 suite and current developments , 2022 .